MicroRNA-21 as an early marker of nephropathy in patients with type 1 diabetes

Mohamed Fouad; Ibrahim Salem; Khaled Elhefnawy; Nermin Raafat; Amal Faisal

doi:10.4103/ijn.IJN_80_19

Advertisment

About us | Subscription | e-Alerts | Feedback | Login

| | | | |

Users Online:742

Official publication of the Indian Society of Nephrology

~ Next article

~ Previous article

~ Table of Contents

~ Similar in PUBMED

~ Search Pubmed for

~ Search in Google Scholar for

~Related articles

~ Citation Manager

~ Access Statistics

~ Reader Comments

~ Email Alert *

~ Add to My List *

* Requires registration (Free)

Article Access Statistics

Viewed	1303

Printed	30

Emailed	0

PDF Downloaded	109

Comments	[Add]

Click on image for details.

ORIGINAL ARTICLE

Year : 2020 | Volume : 30 | Issue : 1 | Page : 21-25

MicroRNA-21 as an early marker of nephropathy in patients with type 1 diabetes

Mohamed Fouad¹, Ibrahim Salem¹, Khaled Elhefnawy¹, Nermin Raafat², Amal Faisal³
¹ Department of Internal Medicine, Faculty of Medicine, Zagazig University, Zagazig, Egypt
² Department of Medical Biochemistry, Faculty of Medicine, Zagazig University, Zagazig, Egypt
³ Department of Internal Medicine, EL Zarka General Hospital, Damietta, Egypt

Correspondence Address:
Dr. Khaled Elhefnawy
Department of Internal Medicine, Faculty of Medicine, Zagazig University, Zagazig
Egypt

Source of Support: None, Conflict of Interest: None

Check

DOI: 10.4103/ijn.IJN_80_19

Introduction: Diabetic nephropathy (DN) is the most common cause of chronic kidney disease worldwide. A major challenge is to identify early diabetic nephropathy. microRNAs (miRNAs) are short noncoding RNA sequences and regulate a wide range of biological processes as cell differentiation, proliferation, cell metabolism and apoptosis. miRNAs may have a role in molecular mechanisms linked to cellular pathways of DN. The aim of this study was to investigate the level of microRNA-21 as a potential marker of early nephropathy in type 1 diabetes mellitus (T1DM). Methods: A total number of 340 participants were included and classified into 3 groups; Group I included 100 healthy participants, Group II included 120 patients with T1DM with <5 years duration, and Group III included 120 patients with T1DM with >5 years duration. All participants were submitted to detail clinical examination, laboratory investigations, urinary albumin/creatinine ratio (ACR), estimated glomerular filtration rate (eGFR) as well as plasma microRNA-21 assays. Results: Blood pressure and ACR were significantly higher in group III than groups I and II. Further, microRNA-21 was significantly higher in group III than groups I and II, and more in group II than group I. microRNA-21 starts to rise in group II before microalbuminuria. miRNA-21 at a level of 0.01 had a greater sensitivity 94.1% and specificity 100% for identifying DN than ACR at level 45 mg/gm with sensitivity 88.2% and specificity 89%. Conclusion: Plasma microRNA-21 can serve as an early marker for diagnosis and identifying diabetic nephropathy in T1DM.

[FULL TEXT] [PDF]*